NCT06291987View on ClinicalTrials.gov

Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation

PHASE1RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

September 19, 2024

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions
Myeloproliferative Neoplasms
Interventions
DRUG

Ivosidenib

Ivosidenib will be given at assigned dose once daily.

DRUG

Ruxolitinib

Ruxolitinib will be given at assigned dose twice daily.

Trial Locations (1)

60637

RECRUITING

University of Chicago Medicine Comprehensive Cancer Center, Chicago

All Listed Sponsors
lead

University of Chicago

OTHER